Neuroprotective Effect of Melatonin on Glucocorticoid Toxicity in the Rat Hippocampus

Analía M. Furio, Ramiro Fontao, Nicolás Falco, Juan I. Ruiz, Roberto Caccuri and Daniel P. Cardinali*

INTRODUCTION

The hippocampus is one of the principal targets for glucocorticoid (GC) action in the brain [1-4]. Two types of corticosteroid receptors are present in the rat hippocampus: type I or mineralocorticoid receptor (MR), and type II or GC receptor (GR), which are able to bind GCs with different affinities. High-affinity MRs are heavily occupied under basal, non-stressed conditions while the lower-affinity GRs are only heavily occupied during stress or after GC administration. It has been documented that MR occupancy mediates salutary GC effects (for example, enhancing hippocampal-dependent cognition and plasticity), whereas GR occupancy has a number of deleterious effects [1-4]. Prolonged GC exposure induces neuromatological changes in the hippocampus, ranging from reversible atrophy of pyramidal CA3 apical dendrites to neuronal loss [4,5]. Hippocampal neuronal damage resulting from continuous exposure to elevated levels of GCs typically occurs over periods longer than 1 week and reflects activation of GRs [6-9]. Even short term treatment of rats with the synthetic GC agonist dexamethasone [10] or with corticosterone potentiates the excitotoxic events of glutamatergic neurotransmission and thus augments hippocampal insult [11,12].

Generation of reactive oxygen species (ROS) presumably plays a major role in decreased cell function and eventual death in rat hippocampus after GC injection [1-4]. Recently, exogenous melatonin was reported as effective in preventing hippocampal neuronal death and cognitive dysfunction that follow maternal deprivation in the developing rat, a situation involving increased GC levels, over-expression of GC receptor genes, and oxidative stress [13]. Indeed, melatonin decreased the expression of GC receptor and increased cell proliferation in the dentate gyrus of maternally deprived neonatal rats [14].

Based on evidence that melatonin is a potent antioxidant and that it has also been demonstrated to reduce the affinity of glucocorticoid receptor in rat brain and to impair GC receptor gene expression [15,16], we carried out the present study, which aimed to assess the occurrence of a neuroprotective effect of melatonin on the degenerative changes of hippocampal nerve cells brought about by dexamethasone treatment in rats.

MATERIALS AND METHODS

Male Wistar rats weighing 250-300 g at the beginning of the experiment were kept under light between 0800 and 2000 h daily and had access to food and water ad libitum. Experiments were carried out in accordance with the European Communities Council Directive (86/609/EEC). A group of 24 rats was treated for 9 days with 0.5 mg/kg of dexamethasone injected s.c. at 0900 h. Half of these animals received 25 μg/ml of melatonin in the drinking water for 10 days, starting 1 day before dexamethasone treatment. Controls included rats that were injected with saline (n=11) or rats injected with saline plus melatonin (n= 10) in the drinking water.

At the end of treatment all rats were killed by decapitation and the brains were fixed for up to 7 days in 4 % paraformaldehyde. Paraffin-included post fixation brains were cut in antero-posterior sections containing all hippocampal regions of both sides, after separation of frontal and occipital lobes. Sections (40 μm) were stained with cresyl violet. Pathological neuronal cells in hippocampal fascia dentate were identified by the following characteristics: nuclear pic-
nosis and retractions, hyperchromatic cytoplasm, global cellular retractions, vacuolizations, apoptotic body and cellular dissolution. Cells showing a nucleolus in the nuclear compartment were considered normal. The morphometric analysis was performed by counting the number of normal and abnormal neurons (defined as necrotic cells) in the left and right hippocampus. Six fields in each slide were randomly selected on each side and were examined at 400 x using a stereological grill in a Carl Zeiss microscope. Results were expressed as percentage of abnormal cells and were statistically analyzed by a one way analysis of variance (ANOVA) followed by Bonferroni’s tests or by a factorial ANOVA.

RESULTS

Fig. (1A-D), depicts the histological appearance of the hippocampus of rats treated with dexamethasone and receiving or not receiving melatonin in the drinking water. Much less abnormal neurons, as represented by picnotic and clusters of cells, were observed in dexamethasone-treated animals receiving melatonin. The morphometric analysis indicated that the percentage of abnormal hippocampal cells was 26.1 ± 1.8 % in rats receiving dexamethasone s.c. and 6.0 ± 1.3 % in rats receiving dexamethasone s.c. and melatonin in the drinking water (p< 0.001). The percentage of abnormal

![Fig. (1). Plates A and C show the histological appearance of the hippocampus of a rat treated for 9 days with dexamethasone. Plates B and D show the histological appearance of the hippocampus of a dexamethasone-injected rat receiving melatonin in the drinking water. Neuronal abnormalities (picnosis, clustering of of cells) are greatly reduced in melatonin-treated animals. Plates E and F show the histological appearance of the hippocampus of vehicle treated rats receiving or not receiving melatonin in the drinking water, respectively. Cresyl violet staining. Magnification: 250 x for plates A, C, E, F; 400 x for plates B and D.](image-url)
hippocampal cells in rats injected with vehicle and receiving or not melatonin in the drinking water did not differ significantly (0.73 ± 0.29 and 0.1 ± 0.1 %, respectively, Fig. (1E, F).

The distribution of abnormal cells in left and right hippocampus is shown in Fig. (2). A factorial ANOVA indicated a significant hippocampal neuronal degeneration after dexamethasone (F_{1,83}= 214, p< 0.00001) which was more pronounced in the left hemisphere (F_{1,83}= 10.7, p< 0.002) and that was impaired by melatonin (F_{1,83}= 81, p< 0.00001). These conclusions were further supported by the significant interactions “dexamethasone x melatonin”, “dexamethasone x side”, “melatonin x side” and “dexamethasone x melatonin x side” detected in the factorial ANOVA (F_{1,83}= 94.6, p< 0.00001; 9.9, p< 0.002; 6.7, p< 0.02 and 7.3, p< 0.008, respectively).

**DISCUSSION**

The current results indicate that melatonin shows a neuroprotective effect against the neurotoxic influence of dexamethasone in the rat hippocampus. This chemical induced degeneration of hippocampal nerve cells as shown by their morphological features.

ROS generation may participate in neuronal death caused by GC in rat hippocampus after GC injection [1-4]. Since oxidative stress is recognized as a strong inducer of apoptosis [17,18] and in view of the remarkable antioxidant activity that melatonin and its metabolites have [19,20], melatonin presumably exerted cytoprotective effects via inhibition of ROS generation and augmentation of the antioxidant defense. However, other possibilities must also be considered. For example, in a study published at the time of submission of the present report, Quiros et al. reported in hippocampal HT22 cells that melatonin prevented glucocorticoid-induced cell death by decreasing receptor translocation to the nuclei in these cells [21].

In a recent study we examined the effect of a daily administration of melatonin for 45 days at two doses (0.5 and 1.0 mg/kg body wt.) on antioxidant status, lipid peroxidation and lipid profile in the brain [22]. Both doses of melatonin caused a significant decrease in brain lipid peroxidation and in the levels of cholesterol, phospholipids, triglycerides and free fatty acids in the brain. Concomitantly, treatment with melatonin augmented the activity of the brain antioxidant enzymes superoxide dismutase, catalase and glutathione peroxidase as well as increased glutathione levels [22].

Melatonin prevented microwave-induced increase in lipid peroxidation of rat hippocampus presumably by strengthening the antioxidant defense system [23]. Likewise, a complete neuroprotection is provided by melatonin against glutamate-induced oxytosis in the HT22 mouse hippocampal cell line [24]. Melatonin reduces pyramidal neuronal death in

![Fig. (2) Percent of abnormal cells in the left and right hippocampus of rats treated for 9 days with 0.5 mg/kg of dexamethasone injected s.c. at 0900 h (n= 24). Half of the animals received 25 μg/ml of melatonin in the drinking water for 10 days before and during dexamethasone treatment. Controls included rats injected with saline and receiving melatonin (n= 11) or not receiving (n= 10) in the drinking water. The morphometric analysis, performed as described in the Methods, indicated a significant hippocampal neuronal degeneration after dexamethasone, which was more pronounced in the left hemisphere and was impaired by melatonin. Letters denote differences in a one way ANOVA, ^a p< 0.01 vs. the remaining means; ^b p< 0.01 vs. rats not injected with dexamethasone of injected with dexamethasone alone. For further statistical analysis, see text.](image-url)
the hippocampus and prevents the impairment of place learning and memory in the Morris water maze following global cerebral ischemia [25]. Therefore, the results indicate that melatonin in pharmacological amounts effectively reduces oxidative stress and has a neuroprotective role in the hippocampus.

There is considerable evidence for lateralization of hippocampal function and hemispheric asymmetry in humans. In the rat, studies have reported asymmetries in the thicknesses of layers, the volumes of hippocampal subfields, and the density of cells at specific points along the septotemporal axis. Recently, significant asymmetries were found in the CA1 and CA3/CA2 hippocampal subfields, with the right hemisphere containing 21% and 6% fewer neurons, respectively [26]. In the present study, hippocampal neuronal degeneration after dexamethasone was more pronounced in the left hemisphere, thus agreeing with previous reports of left dominant asymmetries in the rat brain.

The presence of an atrophied hippocampus is one of the most consistent features of many common psychiatric and neurological disorders, including depression, schizophrenia, bipolar disorder, post-traumatic stress disorder, epilepsy, head injury, and Alzheimer’s disease (AD), as well as aging [27-29]. In many instances, e.g., AD, hippocampal atrophy precedes the development of symptoms while in others, there is a temporal relationship between atrophy and symptomatology. Several factors contribute to hippocampal atrophy, stress being one of the most important through mechanisms involving GC hypersecretion [30-32]. High concentrations of GC are found during periods of stress and during the progression of many pathological conditions such as major depression [33] or AD [34]. Hypercortisolemia can contribute to neuronal injury during the course of these and other diseases, particularly with regard to the hippocampus [35]. Therefore, melatonin that effectively curtails the hippocampal damage caused by GC administration, can be proposed as a potentially beneficial agent to prevent memory loss and learning deficits associated with increased GC levels in an early stage of a number of psychiatric and neurological disorders.

Relevant to these previous findings, in a recent study [36], we reported that melatonin treatment was effective as an add-on drug for treatment of mild cognitive impairment, which is an etiologically heterogeneous syndrome characterized by cognitive impairment in advance of dementia and that converts to AD or other dementia disorders with a rate of approximately 12% per year. Patients receiving 3 – 9 mg of melatonin daily in addition to their standard medication for 9 to 18 months showed a better neuropsychological performance in a number of tests than their non melatonin-treated counterparts. This coincided with a decrease in mood-related symptoms as assessed by the Beck inventory and with an improvement in subjective global assessment of the sleep/wake cycle [36]. It seems feasible that the efficacy of melatonin to improve the clinical condition in mild cognitive impairment depends partly on the effective neuroprotective effect as indicated by our current findings in the rat hippocampus. Further analysis of functional data (e.g., using Morris water maze or radial maze test) to correlate the neuronal damage in hippocampus with the functionality related to spatial learning and memory in dexamethasone-treated rats would shed light on this point.

ACKNOWLEDGEMENTS

This study was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica, Argentina (PICT 14087) and the Universidad de Buenos Aires (ME 075). DPC is a Research Career Awardee from the Argentine Research Council (CONICET).

REFERENCES

Neuroprotective Effect of Melatonin on Glucocorticoid Toxicity


